Press Releases

Title	Topic	Date
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights	Corporate and Finance	5/10/2021
Novavax Statement on Updated PREVENT-19 Trial Protocol	Statement COVID-19	5/10/2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate	COVID-19 Seasonal Influenza	5/10/2021
Novavax Statement in Opposition to the WTO TRIPS Waiver	Statement COVID-19	5/7/2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan	Statement COVID-19	5/7/2021
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility	COVID-19	5/6/2021
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant	COVID-19	5/5/2021
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine	COVID-19	5/3/2021
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021	Corporate and Finance	4/23/2021
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet	Matrix-M™ Adjuvant	4/23/2021